Log In Get Started
Press Releases April 30, 2026 04:01 PM

Xenon to Report Q1 2026 Financial Results on May 7, 2026

Xenon Pharmaceuticals to release Q1 2026 financial results and provide business update on May 7, 2026.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
XENE

Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company, announced it will report its Q1 2026 financial results and provide a business update after U.S. market close on May 7, 2026. The company is advancing clinical trials for its lead drug azetukalner and other ion channel modulators targeting epilepsy, depression, and pain.

Xenon to Report Q1 2026 Financial Results on May 7, 2026
XENE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Xenon Pharmaceuticals will announce Q1 2026 financial results and a business update on May 7, 2026.
  • The lead drug candidate, azetukalner, is in Phase 3 trials for epilepsy and mood disorders such as major depressive disorder and bipolar depression.
  • The company also has early-stage programs focused on potassium and sodium channel modulators for pain management in Phase 1 development.
  • Sectors impacted include biotechnology, pharmaceuticals, neuroscience, and healthcare markets.

VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its first quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, May 7, 2026.

Company Presentation Details:

Date:Thursday, May 7, 2026

Time:4:30pm ET (1:30pm PT)

Webcast:Pre-register here

Dial-In:

(800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID:7898598  

A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.

About Xenon Pharmaceuticals Inc. 

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. 

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner. 

Contacts: 

For Investors:  
Tucker Kelly  
Chief Financial Officer  
[email protected]  

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
[email protected]  


Risks

  • Clinical trial outcomes and regulatory approvals remain uncertain and could impact future revenues and drug commercialization potential.
  • The early-stage pipeline programs carry inherent development risks and may not reach market viability.
  • Biopharmaceutical and healthcare sectors remain sensitive to market, regulatory, and competitive pressures that could affect company performance.

More from Press Releases

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy Jul 7, 2026 Gilat Receives $11 Million in U.S. Department of War Orders, Reinforcing Role in Mission-Critical Defense Connectivity Jul 7, 2026 Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement Jul 7, 2026 ImageneBio Appoints Matt Robbins as General Counsel Jul 7, 2026 AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Jul 7, 2026